Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ppul.26995 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.
Cochrane Database Syst Rev
January 2025
Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.
Background: Cystic fibrosis is a multisystem disease characterised by the production of thick secretions causing recurrent pulmonary infection, often with unusual bacteria. Intravenous (IV) antibiotics are commonly used in the treatment of acute deteriorations in symptoms (pulmonary exacerbations); however, recently the assumption that exacerbations are due to increases in bacterial burden has been questioned. This is an update of a previously published review.
View Article and Find Full Text PDFThirty years of lung transplantation: development of postoperative outcome and survival over three decades.
J Thorac Dis
December 2024
Division of Thoracic Surgery, University Hospital of Munich, LMU, Munich, Germany.
Background: Lung transplantation (LuTX) can be the last resort for patients with end-stage lung diseases. In the last decades, improvements were implemented in transplant medicine, from immunosuppression throughout preservation of the donor organ to enhance lung allograft survival. This retrospective study aims to illustrate the development of the LuTX-program at the University Hospital of Munich, LMU, Munich, Germany, since its launch in 1990 by depicting and comparing postoperative outcome.
View Article and Find Full Text PDFHealth-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases.
Transl Lung Cancer Res
December 2024
Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Background: Health-related quality of life (HRQoL) is critical for patients with lung cancer due to poor prognosis. We presented patient-reported outcomes in patients with non-small cell lung cancer (NSCLC) brain metastases (BM) who received whole-brain radiotherapy (WBRT) in combination with erlotinib or WBRT alone in the phase 3 ENTER study.
Methods: The patients' HRQoL was assessed by using the European Organization for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire (EORTC QLQ-C30).
Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.
Background: Amivantamab has been approved for EGFR exon 20 insertion-mutated non-small-cell lung cancer. The aim of this study was to perform an in-depth analysis of its safety profile.
Research Design And Methods: Safety reports were collected from the database of the Food and Drug Administration Adverse Event Reporting System from April 2021 to September 2023, and the reporting odds ratio (ROR) method was used to detect potential safety signals.
Six radical surgeries for metachronous multiple primary lung cancer: A case report.
Int J Surg Case Rep
January 2025
Department of General Thoracic Surgery, Juntendo University Hospital, Tokyo, Japan.
Introduction And Importance: Comprehensive reports on surgery for metachronous multiple primary lung cancers after the third or subsequent surgeries are lacking. Herein, we report a case in which six radical surgeries were performed for metachronous primary lung cancer.
Case Presentation: The patient was a 62-year-old man when he underwent his first surgery, a right lower lobectomy, and the pathological diagnosis was adenocarcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!